Pharmacokinetic profile of flosequinan in patients with compromised renal function.
暂无分享,去创建一个
[1] R. Falotico,et al. Positive Inotropic and Hemodynamic Properties of Flosequinan, a New Vasodilator, and a Sulfone Metabolite , 1989, Journal of cardiovascular pharmacology.
[2] J. Hampton,et al. Flosequinan in heart failure: acute haemodynamic and longer term symptomatic effects. , 1988, BMJ.
[3] M. Packer,et al. Hemodynamic effects of BTS 49465, a new long-acting systemic vasodilator drug, in patients with severe congestive heart failure. , 1987, American heart journal.
[4] M. Beevers,et al. Standardized methods for comparison of sphygmomanometers. , 1984, Journal of hypertension.
[5] M. Packer,et al. Cumulative Hemodynamic Response to Short‐Term Treatment with Flosequinan (BTS 49465), a New Direct‐Acting Vasodilator Drug, in Severe Chronic Congestive Heart Failure , 1988, Journal of cardiovascular pharmacology.
[6] A. Marmor,et al. The effect of flosequinan in patients with acute-onset heart failure complicating acute myocardial infarction. , 1989, Japanese heart journal.
[7] P. Binkley,et al. Central and regional hemodynamic effects of flosequinan for congestive heart failure. , 1989, The American journal of cardiology.
[8] S. Greenberg,et al. Positive Inotropy Contributes to the Hemodynamic Mechanism of Action of Flosequinan (BTS 49465) in the Intact Dog , 1990, Journal of cardiovascular pharmacology.